丹码生物医药科技

Dancode Biopharmaceuticals is a clinical-stage biotechnology company dedicated to discovering and developing innovative antibody therapeutics through a human genetics-driven approach. Founded by industry veterans with extensive experience at Amgen and other global pharmaceutical leaders, the company utilizes a proprietary platform that integrates large-scale human genomic data with high-throughput antibody engineering. Its primary focus is on oncology and immunology, aiming to increase the probability of clinical success by selecting targets with strong genetic validation. The company's lead programs include novel antibodies targeting CCR8 and bispecific antibodies targeting the TIGIT/PVRIG pathway.